ATE404669T1 - In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide - Google Patents

In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Info

Publication number
ATE404669T1
ATE404669T1 AT01926595T AT01926595T ATE404669T1 AT E404669 T1 ATE404669 T1 AT E404669T1 AT 01926595 T AT01926595 T AT 01926595T AT 01926595 T AT01926595 T AT 01926595T AT E404669 T1 ATE404669 T1 AT E404669T1
Authority
AT
Austria
Prior art keywords
differentially expressed
breast
bladder cancer
polypeptides encoded
present
Prior art date
Application number
AT01926595T
Other languages
German (de)
English (en)
Inventor
Maurice Zauderer
Elizabeth Evans
Melinda Borrello
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE404669T1 publication Critical patent/ATE404669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01926595T 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide ATE404669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04

Publications (1)

Publication Number Publication Date
ATE404669T1 true ATE404669T1 (de) 2008-08-15

Family

ID=22717696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926595T ATE404669T1 (de) 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Country Status (10)

Country Link
US (3) US7268207B2 (enExample)
EP (1) EP1272636B8 (enExample)
JP (1) JP2004502408A (enExample)
CN (2) CN101643732A (enExample)
AT (1) ATE404669T1 (enExample)
AU (2) AU5311901A (enExample)
CA (1) CA2413211A1 (enExample)
DE (1) DE60135315D1 (enExample)
NZ (1) NZ522282A (enExample)
WO (1) WO2001074859A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272636B8 (en) * 2000-04-04 2008-10-08 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
US20020164346A1 (en) * 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CA2488682C (en) * 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
JP2009544574A (ja) * 2006-06-22 2009-12-17 バクシネックス インコーポレーティッド 癌を処置するための抗ｃ３５抗体
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
EP2237792B1 (en) 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
DK2385980T3 (en) 2009-01-08 2018-07-30 Albert Einstein College Medicine Inc BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF
WO2010111792A1 (en) * 2009-04-01 2010-10-07 The University Of British Columbia Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
JP5875518B2 (ja) 2009-09-24 2016-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膀胱がん特異的なリガンドペプチド
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP3389630B1 (en) * 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
WO2019050994A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGEN FOR LYMPHOCYTE THERAPY T
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2019199579A1 (en) 2018-04-09 2019-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
MX2022004657A (es) * 2019-10-18 2022-07-21 Univ Leland Stanford Junior Secuenciacion de tejidos intactos a escala clinica e industrial.
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
NZ255683A (en) 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
WO1994020127A1 (en) 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1272636B8 (en) 2000-04-04 2008-10-08 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU5532601A (en) * 2000-04-12 2001-10-30 Univ Rochester Targeted vaccine delivery systems
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CA2488682C (en) 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
US20050158323A1 (en) 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Also Published As

Publication number Publication date
CA2413211A1 (en) 2001-10-11
US7910551B2 (en) 2011-03-22
CN101643732A (zh) 2010-02-10
EP1272636A2 (en) 2003-01-08
EP1272636B8 (en) 2008-10-08
AU5311901A (en) 2001-10-15
US20070081942A1 (en) 2007-04-12
EP1272636B1 (en) 2008-08-13
NZ522282A (en) 2005-03-24
WO2001074859A2 (en) 2001-10-11
AU2001253119B2 (en) 2006-04-13
US7268207B2 (en) 2007-09-11
US20090312263A1 (en) 2009-12-17
US20020155447A1 (en) 2002-10-24
CN1610743A (zh) 2005-04-27
JP2004502408A (ja) 2004-01-29
WO2001074859A3 (en) 2002-03-28
DE60135315D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE404669T1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
WO2002016413A8 (en) Cripto tumour polypeptide
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
HRP20150432T1 (hr) Indentifikacija antigena povezanih s tumorom za dijagnozu i terapiju
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
EP2070949A3 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
MX2021004425A (es) Vacuna contra cancer de cadena invariante de teleosteo.
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
TR200101702T2 (tr) Mammaglobin, göğse özgü salgılanan bir göğüs kanseri proteini.
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
JP2005524719A5 (enExample)
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE206129T1 (de) Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
WO2003024302A3 (en) Detection and treatment of cancers of breast
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties